المؤلفون: Mocan-Hognogi, R. F., Costin, N., Malutan, A., Ciortea, R., Trif, I. A., Nagy, A. L., Bogdan, M. L., Mihu, D.

المصدر: Folia Morphologica; Vol 75, No 4 (2016); 467-473

مصطلحات موضوعية: anoestrus, hormone replacement therapy, vulvo-vaginal atrophy, oestrogen receptors

الوصف: Background: The purpose of this study was to assess the histological changes occurring in the vagina and vulva in ovariectomised female rats, as well as the response to the administration of injectable oestrogens. Material and methods: We used 30 female Wistar white rats, distributed as follows: group 1 — the control group, group 2 — the operated but untreated rats, and groups 3, 4 and 5 — operated rats, to which oestrogenic treatment was administered (Estradiol, Estradurin, Sintofolin) at a dosage of 0.2 mg/rat/day. After 14 days of treatment, all animals were sacrificed and vaginal and vulvar biopsies were taken from all groups. Results: In group 2, we encountered structural changes of the vaginal mucosa, with severe atrophy and alterations in the thickness of the vagina and vulva. In groups 3, 4 and 5 we found marked hyperplasia of the vaginal and vulvar epithelium, eosinophilic and mast cell infiltration in the chorion. Conclusions: Our study proves that the histopathological changes during anoestrus after administration of oestrogens are cell hyperplasia, thickening of the superficial mucosal layer, eosinophilic and mast cells infiltrations, and chorionic congestion. Furthermore, we demonstrated that Estradiol therapy induces the most evident histological changes when compared to synthetic oestrogens such as Estradurin or Sintofolin.

وصف الملف: application/pdf

العلاقة: https://journals.viamedica.pl/folia_morphologica/article/view/FM.a2016.0026Test

الإتاحة: https://doi.org/10.5603/FM.a2016.0026Test
https://journals.viamedica.pl/folia_morphologica/article/view/FM.a2016.0026Test

المؤلفون: Pintican, Daniela, Iuhas, C., Poienar, Alexandra, Mocan-Hognogi, R., Mihu, D.

المصدر: Obstetrică şi Ginecologie; oct-dec2018, Vol. 66 Issue 4, p171-175, 5p

مصطلحات موضوعية: CAFFEINE, FETAL liver cells, MYOCARDIUM, FETAL development, SEROTONIN receptors

الملخص (بالإنجليزية): Caffeine is one of the most commonly used stimulants in the general population. The effects of caffeine on the body are mediated by interaction with adenosine receptors, adrenergic and cholinergic receptors, gammaaminobutyric acid and serotonin receptors. Testing the research hypothesis was based on a quasi-experimental, transversal, comparative morphological study. The sample in this study included 30 girls from pregnant Wistar rats weighing 180 to 200 g, 16 weeks of age, primates from the Iuliu Haţieganu Biomass at Cluj-Napoca, maintained in appropriate vivarium conditions at the Biobaza of Physiology Discipline. The results suggested that the administration of caffeine in pregnant female rats does not affect the development of fetal organs at the dose of 900mg/day. [ABSTRACT FROM AUTHOR]

Abstract (Romanian): Cafeina este unul dintre stimulentii cei mai frecvent consumati în populatia generală. Efectele cafeinei asupra organismului sunt mediate prin interactiunea cu receptori pentru adenozină, receptori adrenergici si colinergici, acid gama-aminobutiric si receptorii serotoninei. Testarea ipotezei de cercetare s-a bazat pe un studiu morfologic cvasiexperimental, transversal, comparativ. Eşantionul din acest studiu a inclus 30 de feţi proveniţi de la femele gestante de şobolani, rasa Wistar, cu greutate între 180 şi 200 g, în vârstă de 16 săptămâni, primipare provenite din Biobaza UMF „Iuliu Haţieganu", Cluj-Napoca, menţinute în condiţii de vivarium adecvate, la Biobaza Disciplinei de Fiziologie. Rezultatele au sugerat că administrarea de cafeină la femelele gestante de sobolani nu afectează dezvoltarea organelor fetale la doza de 900mg/zi. [ABSTRACT FROM AUTHOR]

: Copyright of Obstetrică şi Ginecologie is the property of Societatea de Obstetrica si Ginecologie and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Dudea-Simon, Marina, Berindan-Neagoe, Ioana, Pop, Laura Ancuţa, Ciortea, R., Măluţan, A., Diculescu, D., Vesa, S., Oancea, Mihaela, Nicula, Renata, Mocan-Hognogi, R., Porumb, C., Mihu, D.

المصدر: Ginecologia.ro; 2022 Supplement 2, Vol. 10, p66-66, 2/3p

مصطلحات موضوعية: CERVIX uteri, PRECANCEROUS conditions, GYNECOLOGIC examination, CERVIX uteri tumors, MIXED infections, LOBULAR carcinoma, CERVICAL cancer

مصطلحات جغرافية: ROMANIA, CLUJ-Napoca (Romania)

الشركة/الكيان: EUROPEAN Union

مستخلص: Introduction/objectives. Romania ranks first regarding the incidence and mortality of cervical cancer (CC) in the European Union. The persistent infection with high-risk HPV subtypes is a confirmed precursor in the development of almost all invasive cervical cancers, with HPV 16 and HPV 18 being classically considered the most common oncogenic subtypes. The prevalence of various HPV strains varies widely across the globe. The objectives of this study were to determine the presence of HPV infection and the infectious viral subtype in patients with normal cervix, CIN and with cervical cancer hospitalized in our institution, as well as to evaluate the particularities of this infection according to certain clinical parameters, in order to prioritize the screening services for patients with high-risk characteristics for HPVinduced disease in our geographic region. Materials and method. A total of 77 patients admitted to the “Dominic Stanca” Clinic of Obstetrics and Gynecology, Cluj-Napoca, were enrolled in the study, grouped in three categories: Group 1 – Control (n=38), Group 2 – CIN (n=30), Group 3 – CC (n=9). For all patients, the diagnosis of the cervical condition was confirmed by histopathological examination. A complex clinical database was developed, followed by the detection of high-risk HPV strains by the HPV Genotypes 14 Real-TM Quant kit. The number of previous cyto-tumoral examinations, as well as the macroscopic appearance of the cervix at the gynecologic examination were also recorded. The SPSS v. 24.0 program was used for data analysis, considering the statistical significance at the standard level of 5%. Results. HPV infection was detected in 88.3% of the subjects and a large number of patients were coinfected with several HPV strains. The most prevalent HR strains were HPV 16, 58, 56, 52, 33 and 31. Considering a single examination, 42% of patients in the control group had abnormal cytological results (PAP III, PAP IV), probably in association with the presence of the HPV infection; however, all patients (100%) in CIN and CC groups had abnormal cytology. At the clinical examination, 26.3% of patients without neoplastic cellular changes had a cervix presenting a macroscopic lesion. When analyzing the appearance of the cervix according to the HPV status, it was found that almost half (44.11%) of the patients with microscopically normal cervix had HPV infection, in 96.8% of cases the detected strain being HPV 16. Conclusions. This study highlighted HPV 16, 58, 56 and 52 as the most prevalent strains in the analyzed population. Given the wide variability in the prevalence of HPV-HR strains by geographical area, it is important to include the most common genotypes in the test kits for each region. The appearance of a cervical lesion is associated in half of the cases with HPV 16 infection, in case of normal cytology. HPV testing could bring additional benefits in guiding the subsequent management for these patients. [ABSTRACT FROM AUTHOR]

: Copyright of Ginecologia.ro is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Suciu, Viorela-Elena, Ciortea, R., Măluțan, A., Iuhaş, C., Mocan-Hognogi, R., Bucuri, Carmen Elena, Rada, Maria, Dudea, Marina, Clim, Adelina, Berindean, Denisa, Mihu, D.

المصدر: Ginecologia.ro; 2020 Supplement, Vol. 8, p26-26, 1/2p

مصطلحات موضوعية: UTERINE artery, PREECLAMPSIA, PLACENTAL growth factor, INTERNATIONAL organization, MULTIPLE pregnancy, TYPE 1 diabetes

مستخلص: Preeclampsia is a multisystemic disease, with a prevalence of 2-5%, that affects pregnant women. Every year, 76,000 women and 500,000 fetuses die due to the complications of this pathology. The prenatal screening for preeclampsia is constantly being updated. Globally, attempts are being made to identify easily reproducible, cost-effective screening markers that determine with great accuracy the patients prone to develop preeclampsia. Thus, there are differences between the described risk factors, the screening and prevention protocols recommended by world-recognized medical associations, such as the International Federation of Obstetrics-Gynecology (FIGO) and the American College of Obstetrics-Gynecology (ACOG). According to the latest FIGO recommendations, all pregnant patients should be screened in the first trimester for preeclampsia, including: maternal risk factors, mean blood pressure, placental growth factor and uterine artery pulsatility index. Patients at increased risk of developing preeclampsia will undergo preventive treatment with aspirin between 11- 14 weeks +/- 6 days and 36 weeks of pregnancy. ACOG presents patients with a history of preeclampsia, multiple pregnancy, chronic hypertension, type 1 or 2 diabetes, kidney disease or autoimmune diseases as having an increased risk of developing preeclampsia and a need for the prophylactic administration of aspirin. There is also a difference between the risk factors presented by the two associations. In conclusion, the determination of screening markers that provide an increased identification of patients at risk of developing preeclampsia, as well as the precise determination of risk factors for preeclampsia are imperative to anticipate and initiate the preventive treatment for women at risk, decreasing the prevalence of the disease, its complications and implicitly the costs. [ABSTRACT FROM AUTHOR]

: Copyright of Ginecologia.ro is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Suciu, Viorela-Elena, Ciortea, R., Măluțan, A., Mocan-Hognogi, R., Bucuri, Carmen Elena, Clim, Adelina, Tiuca, Denisa, Mihu, D.

المصدر: Obstetrică şi Ginecologie; mar-may2019, Vol. 67 Issue 2, p89-89, 1/2p

Abstract (Romanian): Este permisă stimularea ovariană în endometrioză? Prevalența endometriozei este de 50% la femeile infertile, o cifră alarmantă, care generează probleme legate de managementul infertilității asociate, stimularea ovariană devenind o alegere optimă, urmată sau nu de inseminare intrauterină (IIU) ori fertilizare in vitro (FIV)(1). Când este permisă stimularea ovariană în endometrioză? Endometrioza este o boală care afectează femeile aflate la vârstă reproductivă. Vârsta este un factor important în decizia de stimulare ovariană, rezultatele stimulării fiind superioare la vârsta sub 35 de ani. De asemenea, decizia de stimulare ovariană trebuie să țină cont de: stadiul endometriozei, durata infertilității, rezerva ovariană și numărul de foliculi antrali(2). Ce tipuri de stimulări ovariene există? Stimularea poate fi clasificată ca simplă, în cazul rapoartelor sexuale programate și în IIU pe ciclu spontan, sau controlată în cazul IIU și al FIV. Cu ce se face o stimulare eficientă? Stimularea ovariană este de obicei asociată cu IIU sau FIV. În caz de endometrioză asociată cu FIV sunt urmate protocoalele standard de fertilizare. Tratamentul cu analogi de GnRH pentru 3-6 luni înaintea unei tehnici de reproducere asistată (TRA) în endometrioză crește de patru ori șansa de obținere a unei sarcini. Există efecte adverse ale stimulării ovariene în endometrioză? Hiperstimularea ovariană, trombembolismul venos sau reducerea rezervei ovariene sunt principalele efecte adverse. Intervenția chirurgicală poate preceda sau nu stimularea ovariană, existând dovezi contradictorii privind eficacitatea acesteia(1). Inducția ovulatorie în endometrioză este o alternativă realistă? Stimularea ovariană, precedată sau nu de intervenție chirurgicală, urmată sau nu de TRA, s-a dovedit a fi o opțiune bună în tratamentul infertilității asociate endometriozei. [ABSTRACT FROM AUTHOR]

: Copyright of Obstetrică şi Ginecologie is the property of Societatea de Obstetrica si Ginecologie and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)